HC Wainwright Analysts Lower Earnings Estimates for RCUS

Arcus Biosciences, Inc. (NYSE:RCUS) – Equities research analysts at HC Wainwright dropped their Q3 2025 EPS estimates for Arcus Biosciences in a research report issued on Thursday, August 7th. HC Wainwright analyst E. Bodnar now expects that the company will post earnings per share of ($1.32) for the quarter, down from their previous forecast of ($1.24). The consensus estimate for Arcus Biosciences’ current full-year earnings is ($3.15) per share. HC Wainwright also issued estimates for Arcus Biosciences’ Q4 2025 earnings at ($1.19) EPS, FY2025 earnings at ($3.83) EPS, FY2026 earnings at ($4.13) EPS, FY2027 earnings at ($4.32) EPS, FY2028 earnings at ($3.04) EPS and FY2029 earnings at ($1.87) EPS.

Several other brokerages have also recently commented on RCUS. Wells Fargo & Company reduced their price objective on shares of Arcus Biosciences from $26.00 to $25.00 and set an “overweight” rating for the company in a research note on Thursday, August 7th. Barclays reduced their price objective on shares of Arcus Biosciences from $29.00 to $14.00 and set an “overweight” rating for the company in a research note on Wednesday, April 23rd. Morgan Stanley reduced their price objective on shares of Arcus Biosciences from $24.00 to $22.00 and set an “overweight” rating for the company in a research note on Friday, May 9th. Wedbush reiterated an “outperform” rating and issued a $33.00 price objective on shares of Arcus Biosciences in a research note on Wednesday, May 7th. Finally, Wall Street Zen upgraded shares of Arcus Biosciences from a “strong sell” rating to a “hold” rating in a research report on Saturday. Three research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat, Arcus Biosciences presently has an average rating of “Moderate Buy” and an average target price of $21.14.

Arcus Biosciences Stock Up 1.4%

Shares of NYSE RCUS opened at $9.19 on Monday. The company has a quick ratio of 4.50, a current ratio of 4.50 and a debt-to-equity ratio of 0.18. Arcus Biosciences has a 52 week low of $6.50 and a 52 week high of $18.98. The firm has a 50-day moving average price of $9.15 and a 200 day moving average price of $9.38. The stock has a market capitalization of $977.56 million, a price-to-earnings ratio of -2.90 and a beta of 0.89.

Arcus Biosciences (NYSE:RCUS) last announced its quarterly earnings data on Wednesday, August 6th. The company reported ($1.11) EPS for the quarter, beating the consensus estimate of ($1.14) by $0.03. Arcus Biosciences had a negative net margin of 109.56% and a negative return on equity of 55.96%. The firm had revenue of $160.00 million during the quarter, compared to analysts’ expectations of $32.86 million. During the same quarter last year, the business earned ($1.02) earnings per share. The business’s revenue for the quarter was up 310.3% compared to the same quarter last year.

Hedge Funds Weigh In On Arcus Biosciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Gilead Sciences Inc. purchased a new stake in shares of Arcus Biosciences during the fourth quarter worth about $447,610,000. Woodline Partners LP grew its holdings in shares of Arcus Biosciences by 45.5% during the first quarter. Woodline Partners LP now owns 5,127,304 shares of the company’s stock worth $40,249,000 after buying an additional 1,603,367 shares in the last quarter. Boxer Capital Management LLC purchased a new stake in shares of Arcus Biosciences during the fourth quarter worth about $23,857,000. Vanguard Group Inc. grew its holdings in shares of Arcus Biosciences by 24.1% during the first quarter. Vanguard Group Inc. now owns 6,687,800 shares of the company’s stock worth $52,499,000 after buying an additional 1,298,584 shares in the last quarter. Finally, RA Capital Management L.P. purchased a new stake in shares of Arcus Biosciences during the first quarter worth about $8,920,000. Institutional investors and hedge funds own 92.89% of the company’s stock.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.